Overview
Pramlintide is included in this independent research library to separate what has been demonstrated from what remains theoretical. The evidence, regulatory status and terminology vary substantially by compound, so claims should be read in the context of the cited literature.
Pramlintide suggested dosing guide
A concise reference to the dosing ranges most often used in approved labeling, clinical research, or published research discussions. Evidence strength is shown so established dosing is not confused with experimental protocol.
Titration and protocol notes
Increase only as tolerated and reduce mealtime insulin as directed because severe hypoglycemia can occur.
Annotated dosage protocol
Each row explains what the dosage represents. Read it with the evidence badge above: labeled doses, clinical-trial doses, and commonly discussed research amounts do not carry equal clinical weight.
| Phase | Dose | Schedule | What this dosage means |
|---|---|---|---|
| Starting phase | 15 mcg with major meals for type 1 diabetes; 60 mcg for type 2 | Before major meals | The entry dose or lowest studied range, used before any protocol-directed increase. |
| Treatment range | 30–60 mcg (type 1); 60–120 mcg (type 2) | Immediately before major meals | The range used after initiation. The applicable dose depends on the labeled indication or study design. |
| Duration / reassessment | Long-term when prescribed | Reassess before continuing | Increase only as tolerated and reduce mealtime insulin as directed because severe hypoglycemia can occur. Dose changes should never be inferred from vial size or convenient syringe units. |
Pramlintide reconstitution example
This worked example uses a 10 mg vial, 2 mL of diluent, and a 15 mcg reference amount.
Syringe units assume a U-100 syringe. Always verify the vial label, syringe type, formulation, and arithmetic independently.
Safety, handling, and storage
- Suggested ranges are educational summaries, not individualized prescriptions.
- FDA-labeled regimens apply only to the approved product, indication, and delivery system.
- For experimental compounds, human safety, purity, and effective dosing may be unknown.
- Follow product-specific sterility, storage, and beyond-use instructions; do not use damaged or contaminated material.
Pramlintide calculator
Enter your laboratory values to calculate concentration, draw volume, syringe units, and portions per vial.
Deterministic arithmetic for laboratory documentation only. This tool does not select a dose, provide a protocol, or replace qualified medical or laboratory guidance.
Mechanism and research rationale
Acts at amylin receptors and is used clinically alongside mealtime insulin in selected patients. Its effects include slowed gastric emptying, suppressed post-meal glucagon and increased satiety.
Amylin signaling
Diabetes research
Appetite regulation
Key facts
- Evidence tier: FDA-approved drug evidence.
- Research status and regulatory status are not interchangeable.
- This page is an educational reference and does not provide personal medical instructions.